
Veeda Clinical Research Unlisted Share Price
Veeda Clinical Research Limited (CRO)
- CIN
- U73100GJ2004PLC044023
- ISIN
- INE01HQ01026
- Incorporated
- 23 Apr 2004
- Registered state
- Gujarat
Key valuation
- Market cap
- ₹2,990 Cr
- P/E
- —
- Debt / equity
- —
- Shares outstanding
- 6,98,59,813
Prices shown are indicative, dealer-quoted and updated periodically — they are not exchange-traded prices and may differ from the price at which a transaction is finally executed.
Price history
Dated dealer-quote averages, plotted on a true time scale. There is no continuous trading behind these numbers.
About Veeda Clinical Research
Veeda Clinical Research Limited is a contract research organisation (CRO) based in Ahmedabad and founded in 2004. It runs clinical studies for pharmaceutical and biotech companies around the world.
Its services include bioavailability and bioequivalence studies, phase I to IV clinical trials, clinical data management, pharmacovigilance and biostatistics, carried out to international regulatory standards. Binoy Gardi is the CEO and Managing Director.
Veeda reported revenue of ₹715 crore and a net loss of ₹7 crore in FY2026, much smaller than the ₹67 crore loss in FY2025.
Key highlights
- Incorporated in 2004
Financial snapshot
FY2026
- Revenue FY2026
- ₹715.49 Cr
- EBITDA
- ₹226.30 Cr
- PAT
- ₹-6.55 Cr
- Net worth
- —
- Total debt
- ₹421.40 Cr
- Cash & equivalents
- —
- Operating cash flow
- ₹238.72 Cr
- EPS
- ₹-0.94
Management & board
- NJSince 2021
Nitin Jagannath Deshmukh
Director
- BHSince 2026
Binoy Hasmukh Gardi
CEO, Additional Director, Managing Director
- KVSince 2020
Kiran Vithaldas Marthak
Director
- ABSince 2026
Apurva Bhupendra Shah
Additional Director
- VCSince 2018
Vivek Chhachhi
Nominee Director
- VPSince 2025
Vinayak Prabhakar Shenvi
Nominee Director
- RBSince 2021
Rakesh Bhartia
Director
- SNSince 2021
Shankarappa Nagaraja Vinaya Babu
Director
- TASince 2024
Tanushree Akshay Agarwal
Nominee Director
- NASince 2021
Nirmal Atmaram Bhatia
CFO, Company Secretary
- JFSince 2021
Jeanne Frances Taylor Hecht
Director
- DPSince 2024
David Paul Kenny
Director
- GKSince 2025
Georgios Kouvatseas .
Nominee Director
Reported financials · FY2022–FY2026
Figures in ₹ crore unless stated.
| Particulars | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | YoY | CAGR |
|---|---|---|---|---|---|---|---|
| Profit & loss | |||||||
| Revenue from operationsYoY +17.4%CAGR +25.5% | 288 | 410 | 389 | 610 | 715 | +17.4% | +25.5% |
| Other incomeYoY +48.2%CAGR +34.9% | 5 | 11 | 19 | 11 | 17 | +48.2% | +34.9% |
| Total expensesYoY +5.6%CAGR +29.0% | 262 | 358 | 405 | 687 | 725 | +5.6% | +29.0% |
| EBITDAYoY +65.9%CAGR +35.8% | 67 | 114 | 71 | 136 | 226 | +65.9% | +35.8% |
| Depreciation & amortisationYoY +6.2%CAGR +57.7% | 25 | 38 | 53 | 148 | 157 | +6.2% | +57.7% |
| EBITYoY —CAGR +14.0% | 41 | 76 | 18 | -11 | 69 | — | +14.0% |
| Finance costYoY +14.2%CAGR +59.4% | 10 | 14 | 15 | 54 | 62 | +14.2% | +59.4% |
| Profit before taxYoY —CAGR -30.5% | 32 | 62 | 3 | -66 | 7 | — | -30.5% |
| Tax expenseYoY +969.2%CAGR -2.7% | 16 | 17 | 4 | 1 | 14 | +969.2% | -2.7% |
| Profit after tax | 51 | 42 | -0 | -67 | -7 | — | — |
| Earnings per share | ₹7.23 | ₹6.07 | ₹-0.06 | ₹-9.56 | ₹-0.94 | — | — |
| Balance sheet | |||||||
| Net worthYoY -19.1%CAGR +25.4% | 437 | 463 | 1,065 | 862 | — | -19.1% | +25.4% |
| Total debtYoY +3.8%CAGR +62.7% | 60 | 49 | 262 | 406 | 421 | +3.8% | +62.7% |
| Current liabilitiesYoY +2.3%CAGR +30.8% | 151 | 181 | 512 | 433 | 443 | +2.3% | +30.8% |
| Current assetsYoY +25.9%CAGR +16.8% | 312 | 294 | 557 | 462 | 582 | +25.9% | +16.8% |
| Total assetsYoY +9.7%CAGR +31.8% | 678 | 735 | 2,040 | 1,863 | 2,044 | +9.7% | +31.8% |
| Cash flow | |||||||
| Operating activitiesYoY +616.9%CAGR +60.6% | 36 | 106 | 59 | 33 | 239 | +616.9% | +60.6% |
| Investing activities | -154 | -126 | -447 | -149 | -56 | — | — |
| Financing activitiesYoY -215.9%CAGR — | 163 | -1 | 400 | 91 | -106 | -215.9% | — |
| Free cash flowYoY +3721.6%CAGR +132.4% | 7 | 30 | -24 | 6 | 210 | +3721.6% | +132.4% |
| Net change in cashYoY —CAGR +14.4% | 45 | -22 | 12 | -25 | 77 | — | +14.4% |
YoY compares the latest year with the one before it. CAGR runs from the oldest reported year to the latest. A dash means the year is missing, or the starting figure is zero or negative, so a percentage would mislead.
Margins, returns, liquidity, leverage and every other ratio from these figures: see RatiosRevenue, EBITDA and PAT
₹ crore. A year with no reported figure is left out rather than drawn as zero.
- Revenue
- EBITDA
- PAT
Every ratio here is worked out from the reported figures in the Financials tab, and valuation multiples from the indicative price in the header. Nothing is a stored value. A ratio the filings cannot support (a line not reported, or a zero or negative base) is left out or shown as —, never as a misleading number. Balance-sheet ratios use year-end figures.
Valuation multiples
What the indicative price pays for the latest year's earnings, book and cash. On FY2026 figures and the ₹428 indicative price.
- Market cap
- ₹2,990 Cr
- Enterprise value
- ₹3,411 Cr
- Price / sales (P/S)
- 4.18x
- Price / operating cash flow
- 12.53x
- EV / EBITDA
- 15.07x
- EV / EBIT
- 49.16x
- EV / sales
- 4.77x
- Earnings yield
- -0.2%
- Free cash flow yield
- 7.0%
How these are worked out
- Market cap
- Indicative price × shares outstanding
- Enterprise value
- Market cap + debt − cash
- Price / sales (P/S)
- Market cap ÷ revenue from operations
- Price / operating cash flow
- Market cap ÷ cash from operating activities
- EV / EBITDA
- Enterprise value ÷ EBITDA
- EV / EBIT
- Enterprise value ÷ (EBITDA − depreciation)
- EV / sales
- Enterprise value ÷ revenue from operations
- Earnings yield
- PAT ÷ market cap
- Free cash flow yield
- (Operating cash flow − capex) ÷ market cap
IPO / listing status
The company has not announced IPO details such as a DRHP filing, an expected window or its bankers. This section will update once it does.
Research & news
Information currently unavailable
Nothing has been published on Veeda Clinical Research yet. Research, news and articles tagged with it will appear here when they are.
Documents
Private documents are shown locked and are released to verified clients on request.
| Document | Type | FY / date | Access |
|---|---|---|---|
| Annual Report FY 2025-26Annual report · FY 2025-26 · 12.7 MB12.7 MB | Annual report | FY 2025-26 | ViewDownload |
| Annual Report FY 2024-25Annual report · FY 2024-25 · 2.8 MB2.8 MB | Annual report | FY 2024-25 | ViewDownload |
| Annual Report FY 2023-24Annual report · FY 2023-24 · 7.8 MB7.8 MB | Annual report | FY 2023-24 | ViewDownload |
Veeda Clinical Research unlisted shares: FAQs
What is the Veeda Clinical Research unlisted share price today?
The indicative price of Veeda Clinical Research Limited (CRO) shares is ₹428 per share, as of 17 Nov 2026. Unlisted shares have no exchange price: this figure reflects recent off-market deals and can differ from the price on a particular trade. The price history on this page shows how it has moved.
How can I buy Veeda Clinical Research unlisted shares?
Raise a buy enquiry on this page with the number of shares you want. Our desk confirms availability and the price, you pay from a bank account in your own name, and the shares are transferred to your demat account. You need a PAN and a demat account with any depository participant.
How can I sell Veeda Clinical Research shares?
Raise a sell enquiry with the number of shares you hold in demat. Once the price is agreed, you transfer the shares from your demat account and the money is paid to a bank account in your name.
Is Veeda Clinical Research planning an IPO?
Veeda Clinical Research Limited (CRO) is currently at the "Pre-IPO" stage. No IPO date has been announced. A listing depends on the company and on regulatory approval.
What are Veeda Clinical Research's revenue and profit?
In FY26, Veeda Clinical Research Limited (CRO) reported revenue of ₹715 Cr and a loss of ₹7 Cr. The Financials section has the full statements for every year we hold.
Is it legal to buy unlisted shares in India?
Yes. Shares of unlisted public companies can be bought and sold off-market and transferred between demat accounts. They carry more risk than listed shares: prices are not set on an exchange, it can take time to find a buyer, and a listing is never guaranteed.
Is there a lock-in on Veeda Clinical Research shares after the IPO?
SEBI rules lock in shares held before an IPO for a period after listing, currently six months from allotment for most investors in a mainboard IPO. Shares bought now in the unlisted market would usually be covered by this lock-in.
How are gains on Veeda Clinical Research unlisted shares taxed?
Gains on unlisted shares held for more than 24 months are long-term capital gains; held for less, they are short-term and taxed at your slab rate. Check the current rates with a tax adviser before you sell.

